TXNDC17 Protein

Produktnummer ABIN7198224

Dieses Recombinant TXNDC17-Protein wird in Escherichia coli (E. coli) produziert.

Kurzübersicht für TXNDC17 Protein (ABIN7198224)

Target: TXNDC17 (Thioredoxin Domain Containing 17 (TXNDC17))

Protein-Typ: Recombinant

Spezies: Human

Quelle: Escherichia coli (E. coli)

Reinheit: > 97 % as determined by reducing SDS-PAGE.

Produktdetails

Verwendungszweck: Recombinant Human TXNDC17/TRP14/TXNL5 Protein

Sequenz: Met 1-Asp 123

Produktmerkmale: A DNA sequence encoding the mature form of human TXNDC17 (Q9BRA2) (Met 1-Asp 123) was expressed and purified, with an initial Met.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Antigendetails

Target: TXNDC17 (Thioredoxin Domain Containing 17 (TXNDC17))

Andere Bezeichnung: TXNDC17//TXNL5

Hintergrund:

Background: Cell surface A33 antigen, also known as glycoprotein A33, is a single-pass type I  membrane protein which is expressed in normal gastrointestinal epithelium and in 95% of colon cancers. GPA33 contains one Ig-like C2-type (immunoglobulin-like) domain and one Ig-like V-type (immunoglobulin-like) domain. The open reading frame encodes a 319-amino acid polypeptide having a putative secretory signal sequence and 3 potential glycosylation sites. The predicted mature protein has a 213-amino acid extracellular region, a single transmembrane domain, and a 62-amino acid intracellular tail. Intracellular traffic and recycling to the cell surface appear to play a major role in GPA33 function and to have an influence on its surface density superseding translational regulation. GPA33 has become a promising target of immunologic therapy strategies, but its biologic function and potential role in tumorigenesis are unknown. EpCAM protein and GPA33 mRNA expressions are specific and sensitive markers of Barrett's metaplasia (BM). GPA33 may also play a role in cell-cell recognition and signaling.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Synonym: TRP14;TXNL5

Molekulargewicht: 13.9 kDa

UniProt: Q9BRA2